التفاصيل البيبلوغرافية
| العنوان: |
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. |
| المؤلفون: |
Gaspar, H Bobby, Parsley, Kathryn L, Howe, Steven, King, Doug, Gilmour, Kimberly C, Sinclair, Joanna, Brouns, Gaby, Schmidt, Manfred, Kalle, Christof Von, Barington, Torben, Jakobsen, Marianne A, Christensen, Hans O, Ghonaium, Abdulaziz Al, White, Harry N, Smith, John L, Levinsky, Prof Roland J, Ali, Prof Robin R, Kinnon, Prof Christine, Thrasher, Prof Adrian J |
| المصدر: |
Lancet (0099-5355); Dec2004, Vol. 364 Issue 9452, p2181-2187, 7p |
| مستخلص: |
Background X-linked severe combined immunodeficiency (SCID-X1) is caused by mutations in the common cytokine-receptor γ chain (γc), resulting in disruption of development of T lymphocytes and natural-killer cells. B-lymphocyte function is also intrinsically compromised. Allogeneic bone-marrow transplantation is successful if HLA-matched family donors are available, but HLA-mismatched procedures are associated with substantial morbidity and mortality. We investigated the application of somatic gene therapy by use of a gibbon-ape-leukaemia-virus pseudotyped gammaretroviral vector.Methods Four children with SCID-X1 were enrolled. Autologous CD34-positive haemopoietic bone-marrow stem cells were transduced ex vivo and returned to the patients without preceding cytoreductive chemotherapy. The patients were monitored for integration and expression of the γc vector and for functional immunological recovery.Findings All patients have shown substantial improvements in clinical and immunological features, and prophylactic medication could be withdrawn in two. No serious adverse events have been recorded. T cells responded normally to mitogenic and antigenic stimuli, and the T-cell-receptor (TCR) repertoire was highly diverse. Where assessable, humoral immunity, in terms of antibody production, was also restored and associated with increasing rates of somatic mutation in immunoglobulin genes.Interpretation Gene therapy for SCID-X1 is a highly effective strategy for restoration of functional cellular and humoral immunity. [Copyright &y& Elsevier] |
|
Copyright of Lancet (0099-5355) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
